Sign in Subscribe

Zenas BioPharma Secures $2B+ Deal for MS Drug from InnoCare

Zenas BioPharma acquires global rights to orelabrutinib, an experimental multiple sclerosis drug from InnoCare Pharma, in a licensing deal worth over $2 billion with $120M funding secured.

Zenas BioPharma Secures $2B+ Deal for MS Drug from InnoCare
Photo by National Institute of Allergy and Infectious Diseases on Unsplash
Already have an account? Sign in.